|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.00 GBX | -1.39% |
|
+5.19% | +22.41% |
| 24/02 | Avacta hails new data supporting proprietary preCision platform | AN |
| 24/02 | Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 41Cr | - | - | |||
| 4.3TCr | |||||
| 3.92TCr | |||||
| 3.01TCr | - | ||||
| 2.19TCr | - | ||||
| 1.82TCr |
- Stock Market
- Equities
- AVCT Stock
- Charts Avacta Group Plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition